Development of new dosage forms with uncompromised efficacy, safety and stability and improved tolerability and dosage regimen that would result in better patient compliance is an imperative in modern pharmacotherapy. Patients" adherence to dosage regimen is of great importance, especially when prolonged treatment is an issue. Therefore, novelties in formulation development for antidepressants and anxiolytics are directed towards the modified/sustained or extended release drug products and orally disintegrating tablets. There is a number and variety of new technologies employed with this respect. In the present paper, an overview of the most important technologies applied in commercially available drug products within the group of antidepressants and anxiolytics is given.
TY - JOUR
AU - Parojčić, Jelena
AU - Ibrić, Svetlana
AU - Đurić, Zorica
PY - 2007
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/961
AB - Development of new dosage forms with uncompromised efficacy, safety and stability and improved tolerability and dosage regimen that would result in better patient compliance is an imperative in modern pharmacotherapy. Patients" adherence to dosage regimen is of great importance, especially when prolonged treatment is an issue. Therefore, novelties in formulation development for antidepressants and anxiolytics are directed towards the modified/sustained or extended release drug products and orally disintegrating tablets. There is a number and variety of new technologies employed with this respect. In the present paper, an overview of the most important technologies applied in commercially available drug products within the group of antidepressants and anxiolytics is given.
PB - Savez farmaceutskih udruženja Srbije, Beograd
T2 - Arhiv za farmaciju
T1 - Antidepressants and anxiolytics: Novel tablet formulations
T1 - Antidepresivi i anksiolitici - novine u formulaciji tableta
VL - 57
IS - 1-2
SP - 94
EP - 105
UR - https://hdl.handle.net/21.15107/rcub_farfar_961
ER -
@article{
author = "Parojčić, Jelena and Ibrić, Svetlana and Đurić, Zorica",
year = "2007",
abstract = "Development of new dosage forms with uncompromised efficacy, safety and stability and improved tolerability and dosage regimen that would result in better patient compliance is an imperative in modern pharmacotherapy. Patients" adherence to dosage regimen is of great importance, especially when prolonged treatment is an issue. Therefore, novelties in formulation development for antidepressants and anxiolytics are directed towards the modified/sustained or extended release drug products and orally disintegrating tablets. There is a number and variety of new technologies employed with this respect. In the present paper, an overview of the most important technologies applied in commercially available drug products within the group of antidepressants and anxiolytics is given.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Antidepressants and anxiolytics: Novel tablet formulations, Antidepresivi i anksiolitici - novine u formulaciji tableta",
volume = "57",
number = "1-2",
pages = "94-105",
url = "https://hdl.handle.net/21.15107/rcub_farfar_961"
}
Parojčić, J., Ibrić, S.,& Đurić, Z.. (2007). Antidepressants and anxiolytics: Novel tablet formulations. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 57(1-2), 94-105.
https://hdl.handle.net/21.15107/rcub_farfar_961
Parojčić J, Ibrić S, Đurić Z. Antidepressants and anxiolytics: Novel tablet formulations. in Arhiv za farmaciju. 2007;57(1-2):94-105.
https://hdl.handle.net/21.15107/rcub_farfar_961 .
Parojčić, Jelena, Ibrić, Svetlana, Đurić, Zorica, "Antidepressants and anxiolytics: Novel tablet formulations" in Arhiv za farmaciju, 57, no. 1-2 (2007):94-105,
https://hdl.handle.net/21.15107/rcub_farfar_961 .
